Clinical Trials Browser

Withdrawn × INDUSTRY × asparaginase erwinia chrysanthemi recombinant × Clear all

NCT02150928 2015-05-13

An Open-Label, Single-Arm, Multicenter Pharmacokinetic Study of Intramuscular Erwinaze® (Asparaginase Erwinia Chrysanthemi)/Erwinase® (Crisantaspase)

Phase 2 Withdrawn

LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma